Naproxen glycine conjugate-synthesis, pharmaceutical preformulation and pharmacodynamic evaluation

Drug Delivery

Volumn 19, Issue 2, 2012, Pages 102-111

  Mishra, Ashutosh ^a   Agrawal, Shalini ^a   Pathak, Kamla ^a  

^a Rajiv Academy for Pharmacy ^*  (India)

Author keywords

Antiinflammatory potential; Naproxen glycine conjugate; Preformulation; Synthesis

Indexed keywords

GLYCINE; NAPROXEN;

AMINO ACID SYNTHESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON; COLON ULCER; CONJUGATE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MELTING POINT; NUCLEAR MAGNETIC RESONANCE; PARTITION COEFFICIENT; PH; PHARMACODYNAMICS; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY; X RAY DIFFRACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; COLITIS; COLON; DRUG DELIVERY SYSTEMS; GLYCINE; HYDROGEN-ION CONCENTRATION; NAPROXEN; PERMEABILITY; PRODRUGS; RATS; SOLUBILITY;

EID: 84856399882     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2011.649218     Document Type: Article

References (25)

1. Akala EO, Elekwachi O, Chase V, Johnson H, Marjorie L, Scott K. 2003. Organic redox initiated polymerization process for the fabrication of hydrogel for colon specific drug delivery. Drug Dev. Ind. Pharm. 29(4): 375-386. (Pubitemid 36528605)
2. Amidon GL, Lessman GD, Elliot RL.1980. Improving intestinal absorption of water insoluble drugs: A membrane metabolism strategy. J. Pharm. Sci. 69: 1363-1368. (Pubitemid 11172810)
3. Aulton ME. 2002. Pharmaceutics, 'The Science of Dosage form Design', 2nd Edition, New York. Churchill Livingstone, 114-138.
4. Babazadeh M. 2008. Design, synthesis and in-vitro evaluation of vinyl ether type polymeric prodrug of ibuprofen, ketoprofen and naproxen. Int. J. Pharm. 356: 167-173.
5. Basit A., Bloor J. 2003. Prespectives on colonic drug delivery. Business Briefing: Pharma TeC.H. 185-190.
6. Canavary M, Bruni P, Cardin M, Pasut G, Varinose FM. 2009. Polyethylene-mesealazine conjugate for colon specific delivery. Int. J. Pharm. 368,171-177.
7. Chien YW. 2005. Novel Drug Delivery System, 2nd edition, New York: Marcel Dekker Inc. 163p.
8. Florey K.2005. Analytical profile of Drug substance and excipients. Vol 21, New York. Academic Press. 348p.
9. Gilman AG, Hardman JG, Limbird LE. 2005. Goodman and Gilman's: The Pharmacological Basis of therapeutics. 10th edition, New York. Mc Graw Hill publication. 671p.
10. Habib MM, Hodgson HJ, Davidson BR. 2006. The role of glycine in hepatic ischemia-reperfusion injury. Curr. Pharm. Design. 12: 2953-2967. (Pubitemid 44184628)
11. Jung Y, Kim HH, Kim H, Kong H, Choi B, Yang Y, Kim Y. 2006. Evaluation of 5-aminsalicylictaurine as a colon specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis. Eur. J. Pharm. Sci. 28: 26-33.
12. Kamel AHE, Aziz AMA, Subhagh HIE. 2008. Oral colon targeted delivery system for treatment of inflammatory bowel disease: synthesis, in vitro and in vivo assessment. Int. J. Pharm. 358: 248-255.
13. Lichtenberger LM, Romero JJ, Dial EJ, Moore JE. 2008. Naproxen-PC: A GI safe and highly effective anti-inflammatory. Inflammopharmacology. 16: 1-5.
14. Maffat AC, Osselton MD, Widdop B. 2004. Clarke's Analysis of Drug and Poisons, 3rd Edition, Vol. 2. Chicago, Pharmaceutical Press, 1027-1028.
15. The Complete Drug reference. 2002. 23rd edition, Edited by Sweetman, London, Pharmaceutical Press, p1365.
16. Millar AD, Rampton DS, Chander CL, Claxson AWD, Blades S, Coumbe A, Panetta J, Morris CJ, Blake DR. 1996. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut. 39: 407-415. (Pubitemid 26338530)
17. Philip AK, Dubey RK, Pathak K. 2008. Optimizing delivery of flurbiprofen to the colon using a targeted prodrug approaC.H. J. Pharm. Pharmacol. 60: 607-613. (Pubitemid 351589048)
18. Philip AK, Dabas S, Pathak K. 2009. Optimized prodrug approach: A means for achieving enhanced anti-inflammatory potential in experimentally induced colitis, J. Drug Target. 17: 235-241.
19. Polce MJ, Ren D, Wesdemiotis C. 2000. Dissociation of peptide bond in protonated peptides. J. Mass Spectrom. 35: 1391-1398. (Pubitemid 32063645)
20. Prasad R, Krishnaiah YSR and Satyanarayan S. 1996. Trends in colonic drug delvery: A review. Indian Drugs. 33: 1-10. (Pubitemid 26248119)
21. Rautio J, Nevalain T, Taipale H, Gyuther J, Laine K. 2000. Piperazinyl alkyl prodrug of naproxen improve in-vitro skin permeation. Eur. J. Pharm. Sci. 11: 157-163. (Pubitemid 30479857)
22. Sheha M, Khedr A, Elsherief H. 2002. Biological and metabolic study of naproxen-propyphenazone mutual prodrug. Eur. J. Pharm. Sci. 17: 121-130. (Pubitemid 35248265)
23. Singh A P, Ramadan WM, Dahiya R, Sarpal AS, Pathak K. 2009. Product development studies of amino acid conjugate of aceclofenac, Curr. Drug Del. 6: 208-216.
24. Yang L, Chu JS, Fix JA. 2002. Colon specific drug delivery: New approaches and in vitro/ in vivo evaluation. Int J Pharm. 235: 1-15. (Pubitemid 34185432)
25. Zou M, Okamoto H, Hao X, Sun J, Cui F, Danjo K. 2005. Synthesis and properties of polysaccharide prodrug of 5-amino salicylic acid as potential colon specific delivery system. Eur. J. Pharm. Biopharm. 59: 155-160. (Pubitemid 39573448)